TrialBreaks is an independent biomedicine media brand covering the clinical trial results, biomedical discoveries, and breakthrough therapies shaping the future of medicine.Every Tuesday and Thursday, we release Last Week in Biomedicine — a 15–20 minute podcast available on Spotify, Apple Podcasts, and Amazon Music. Tuesday episodes feature Part 1, and Thursday episodes feature Part 2, together breaking down ten of the previous week’s most significant biopharma stories, including major Phase 2 and Phase 3 clinical trial readouts, FDA updates, and emerging therapeutic advances.Throughout the week, we post concise updates on Facebook and Instagram covering important clinical trial results, biomedical discoveries, and emerging developments across biotech and translational medicine.Built for researchers, clinicians, students, biotech investors, patients, and anyone interested in the next generation of healthcare, TrialBreaks aims to make complex biomedical developments accessible without losing scientific rigor.Our podcast uses AI-assisted narration generated from curated research materials. We select, curate, and review all source material to ensure accuracy, clarity, and scientific integrity. We disclose this openly because transparency about how biomedical media is created matters.Every drug, endpoint, and effect size we discuss is traced back to primary sources, including peer-reviewed publications, sponsor press releases, regulatory filings, and scientific conference presentations. Editorial coverage is independent and not influenced by sponsors or companies. If we make an error, we correct it in a future post or episode.
About
TrialBreaks is an independent biomedicine media brand covering the clinical trial results, biomedical discoveries, and breakthrough therapies shaping the future of medicine.Every Tuesday and Thursday, we release Last Week in Biomedicine on Spotify, Apple Podcasts, and Amazon Music that breaks down ten of the previous week’s most significant biopharma stories, including major Phase 2 and Phase 3 clinical trial readouts, FDA updates, and emerging therapeutic advances.Throughout the week, we post concise updates on Facebook and Instagram covering important clinical trial results, biomedical discoveries, and rapidly developing stories across biotech, medicine, and healthcare research.Built for researchers, clinicians, students, biotech investors, patients, and anyone interested in the next generation of healthcare, TrialBreaks aims to make complex biomedical developments accessible without losing scientific rigor.Our weekly podcast is produced using Google’s NotebookLM, which generates an AI-narrated audio briefing from a curated research package. We select, curate, and review all source material; the AI handles narration and audio generation. We disclose this openly because audiences deserve transparency about how the content they consume is created.Every drug, endpoint, and effect size we discuss is traced back to a primary source, including peer-reviewed publications, sponsor press releases, regulatory filings, or scientific conference presentations. Editorial coverage is independent and not influenced by sponsors or companies. If we make an error, we correct it in a future post or episode.
Legal
This page covers our medical disclaimer and privacy policy in plain language.Medical disclaimer. TrialBreaks publishes plain-language summaries of publicly reported clinical trial results and biomedical research. The content is for general educational purposes only. It is not medical advice, diagnosis, or treatment. A positive Phase 2 or Phase 3 trial result means a single trial met its endpoint — not that a drug is safe, available, or right for any individual. If you're considering changes to your treatment, talk to a qualified clinician who knows your medical history. In a medical emergency, contact emergency services immediately.No medical or investment advice. The AI-generated narration on our podcast is not a licensed medical professional, and coverage of a trial, drug, or developer does not constitute endorsement. Some listeners follow clinical trial news for investment purposes — TrialBreaks is not investment advice. Consult a licensed financial advisor before making investment decisions.Privacy. We collect the minimum information needed to operate the show — server logs (IP, browser, timestamp, retained 90 days), and your email address if you contact us or sign up for a newsletter. We do not sell your information. We do not use it for advertising. Podcast listening data is governed by each platform's own policies (Spotify, Apple Podcasts, Amazon Music, etc.) — not ours.Third-party services. To operate TrialBreaks we use Cloudflare (hosting + DNS), Carrd (this website), Spotify for Creators (podcast hosting), Anthropic (AI-assisted research), and Google NotebookLM (podcast audio generation). Each operates under its own privacy policy.Your rights. Depending on where you live, you may have the right to access, correct, or delete the personal information we hold about you. Email [email protected] to exercise these rights.Corrections. If you spot a factual error in any episode or post, email [email protected]. We address corrections on the next episode and on this site.Last updated: May 13, 2026.
Contact
We read every email. Reasonable response time is 2–3 business days.General inquiries: [email protected]
Corrections: [email protected]
Press and interviews: [email protected]
Sponsorship and partnerships: [email protected]
Privacy and legal: [email protected]Find us on the platforms: Spotify, Apple Podcasts, Amazon Music, Pocket Casts, Overcast, Castbox.Please do not send unsolicited drug recommendations, investment advice requests, or personal medical questions. For medical questions, please consult a licensed clinician (see Legal).